Current Lipid Management Guidelines in Atherosclerotic Cardiovascular Disease
Published: 2022-06-20
Page: 212-219
Issue: 2022 - Volume 5 [Issue 1]
Muneera Al-Taweel *
King Abdulaziz Hospital, MNGHA, Al Ahsa, Saudi Arabia and King Abdullah International Medical Research Center (KAIMRC), Al Ahsa, Saudi Arabia.
Faisal AlAnazi
King Abdulaziz Hospital, MNGHA, Al Ahsa, Saudi Arabia.
Sarah Al-Mukhaylid
King Abdullah International Medical Research Center (KAIMRC), Al Ahsa, Saudi Arabia and College of Applied Medical Sciences (CoAMS-A), King Saud Bin Abdulaziz University for Health Sciences / KAIMRC/ KAH, National Guard Health Affairs, Al-Ahsa, Saudi Arabia.
Abdulwahab Alkhashram
King Abdulaziz Hospital, MNGHA, Al Ahsa, Saudi Arabia.
Gousay Alkhazmari
Imam Abdulrahman Bin Faisal Hospital, MNGHA Dammam, Saudi Arabia.
Faisal Abushullaih
Imam Abdulrahman Bin Faisal Hospital, MNGHA Dammam, Saudi Arabia.
*Author to whom correspondence should be addressed.
Abstract
The use of coronary artery calcium (CAC) score to reclassify risk individuals at either borderline or intermediate risk, for whom the danger of statin therapy is unknown, is another significant addition to the 2018 recommendations. Increased risk of recurrent cardiovascular (CV) events is linked to having established atherosclerotic cardiovascular disease (ASCVD). Many modifiable risk factors for cardiovascular disease have been connected in the literature, including blood pressure, low-density lipoprotein (LDL), high-density lipoprotein (HDL), glucose intolerance, and smoking. High dose statins and strict adherence to dietary and lifestyle changes have been shown to reduce the risk of coronary events, with the advent of newer lipid-lowering medications, statins may one day become obsolete.
Keywords: High-density lipoprotein, cardiovascular disease, coronary artery calcium, Atherosclerosis